Lactate activates CCL18 expression via H3K18 lactylation in macrophages to promote tumorigenesis of ovarian cancer.

This study investigates the role of lactate in the genesis and progression of ovarian cancer (OV) and explores the underlying mechanisms. Serum lactate levels show a positive correlation with tumor grade and poor prognosis in patients with OV. Bioinformatics analysis identifies as a lactate-related gene in OV.

Analysis of prognostic value of lactate metabolism-related genes in ovarian cancer based on bioinformatics.

Background: Recent studies have provided evidence supporting the functional role and mechanism of lactate in suppressing anticancer immunity. However, there is no systematic analysis of lactate metabolism-related genes (LMRGs) and ovarian cancer (OV) prognosis.

Results: Six genes (CCL18, CCND1, MXRA5, NRBP2, OLFML2B and THY1) were selected as prognostic genes and a prognostic model was utilized.

RPL35A drives ovarian cancer progression by promoting the binding of YY1 to CTCF promoter.

Ovarian cancer is one of the most common gynaecological malignancies with poor prognosis and lack of effective treatment. The improvement of the situation of ovarian cancer urgently requires the exploration of its molecular mechanism to develop more effective molecular targeted drugs. In this study, the role of human ribosomal protein l35a (RPL35A) in ovarian cancer was explored in vitro and in vivo.

1-MT inhibits the invasion of CBP-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function.

Background: The indoleamine 2, 3-dioxygenase (IDO) inhibitor 1-methyl-tryptophan (1-MT) is currently being used in clinical trials in patients with relapsed or refractory solid tumors by inhibiting tumor immune escape. A greater understanding of IDO activity is required to begin to understand the molecular mechanism by which drugs work. This study was conducted to investigate of the clinical significance of 1-methyl-tryptophan (1-MT) in treating carboplatin-resistant (CBP-resistant) ovarian cancer and its mechanism of action.

[Immune reconstitution in advanced ovarian cancer patients undergoing first line chemotherapy].

Aim: We investigated the numbers and proportions of lymphocyte subsets in advanced ovarian cancer patients undergoing chemotherapy, so as to identify whether there is immune reconstitution after chemotherapy, and seek rational chemo-immunotherapy strategies in ovarian cancer treatment.

Methods: Blood samples from each ovarian cancer patient were obtained before (S(0)) and at day 5-7 (S(1)), day 12-14 (S(2)) and day 25-28 (S(3)) after chemotherapy in 13 patients. Flow cytometry technique was employed to analyse the numbers, proportions of CD3(+), CD4(+), CD8(+), CD4(+) CD25(+) Treg and memory-like phenotype lymphocyte subsets.

The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy.

Till now, little is known about the effects of chemotherapy on the immunity of cancer patients and the ideal timing ("window" period) for immunotherapy combined with chemotherapy. In this study, we addressed the immunogenicity of apoptotic ovarian cancer cells induced by paclitaxel and carboplatin, the immunologic aspects in ovarian cancer patients under chemotherapy, and the CTL response when CD8(+) T cells were stimulated with tumor antigen in the "window" period. The immunogenicity of apoptotic ovarian cancer cells was detected first.

[Effect of apoptotic ovarian cancer cells induced by paclitaxel-cisplatin on antigen presentation function of DC].

Aim: To explore wheather apoptotic ovarian cancer cells induced by paclitaxel-cisplatin could be cross-presented by antigen presenting cells and promote immune responses.

Methods: DCs were generated from peripheral blood monocytes in RPMI1640 supplemented with GM-CSF and IL-4. After 6 days' incubation, DCs were further co-cultured with either apoptotic HO8910 cell lines induced by paclitaxel-cisplatin or control cells for four hours.